• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

科威特阿拉伯人群及静脉血栓形成患者中活化蛋白C抵抗和凝血因子V莱顿突变的高患病率。

High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.

作者信息

Jadaon Mehrez M, Dashti Ali A, Lewis Hend L

机构信息

Department of Medical Laboratory Sciences, Kuwait University, Kuwait.

出版信息

Diagn Mol Pathol. 2010 Sep;19(3):180-3. doi: 10.1097/00019606-201009000-00009.

DOI:10.1097/00019606-201009000-00009
PMID:20736749
Abstract

INTRODUCTION

Activated protein C resistance (APC-R) because of clotting factor V Leiden mutation (FVL; Arg506Gln; G1691A) is a risk factor for the development of venous thromboembolic disorders (VTE). APC-R/FVL was reported to be very high in White patients with VTE (15% to 65%) and healthy populations (1% to 15%), and to be very low or absent in non-White patients. Studies on Arab patients and populations were very inconsistent. This study reports APC-R and FVL in Arabs living in Kuwait.

MATERIALS AND METHODS

Whole venous blood samples were collected from 400 patients with VTE and 200 healthy controls, all of whom were of Arab ethnicity living in Kuwait. The samples were used to separate plasma for an APC-R test, and DNA extraction for polymerase chain reaction and restricted fragment length polymorphism were performed. APC-R was on an automated hemostasis analyzer, and values less than 2.0 were reported as APC-R. Polymerase chain reaction and restricted fragment length polymorphism tests were performed using standard methods, and the results were reported as normal wild-type homozygous GG, FVL homozygous AA, or FVL heterozygous GA.

RESULTS

Sixty-three out of 400 patients (15.75%) and 4 out of 200 healthy controls (2%) had APC-R and at least one copy of FVL. Fifty-one patients and 4 controls were heterozygous whereas only 12 patients were homozygous.

CONCLUSION

The prevalence of APC-R and FVL is quite high in Arabs living in Kuwait, being comparable with the prevalence reported in Whites, although being toward the lowest values reported there.

摘要

引言

由于凝血因子V莱顿突变(FVL;Arg506Gln;G1691A)导致的活化蛋白C抵抗(APC-R)是静脉血栓栓塞性疾病(VTE)发生的一个危险因素。据报道,VTE白人患者(15%至65%)和健康人群(1%至15%)中APC-R/FVL非常高,而非白人患者中则非常低或不存在。对阿拉伯患者和人群的研究结果非常不一致。本研究报告了居住在科威特的阿拉伯人中的APC-R和FVL情况。

材料与方法

从400例VTE患者和200例健康对照中采集全静脉血样本,所有受试者均为居住在科威特的阿拉伯族裔。采集的样本用于分离血浆以进行APC-R检测,并进行DNA提取用于聚合酶链反应和限制性片段长度多态性分析。APC-R检测在自动止血分析仪上进行,小于2.0的值报告为APC-R。聚合酶链反应和限制性片段长度多态性检测采用标准方法进行,结果报告为正常野生型纯合子GG、FVL纯合子AA或FVL杂合子GA。

结果

400例患者中有63例(15.75%)和200例健康对照中有4例(2%)存在APC-R且至少有一份FVL拷贝。51例患者和4例对照为杂合子,而只有12例患者为纯合子。

结论

居住在科威特的阿拉伯人中APC-R和FVL的患病率相当高,与白人中报告的患病率相当,尽管处于该报告中最低值的范围。

相似文献

1
High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.科威特阿拉伯人群及静脉血栓形成患者中活化蛋白C抵抗和凝血因子V莱顿突变的高患病率。
Diagn Mol Pathol. 2010 Sep;19(3):180-3. doi: 10.1097/00019606-201009000-00009.
2
Factor V Leiden mutation in Arabs in Kuwait by real-time PCR: different values for different Arabs.实时 PCR 检测科威特阿拉伯人中的因子 V 莱顿突变:不同的阿拉伯人有不同的值。
J Hum Genet. 2010 Apr;55(4):232-5. doi: 10.1038/jhg.2010.11. Epub 2010 Mar 12.
3
Factor V Kuwait: a novel mutation in the coagulation factor V gene discovered in Kuwait.
Med Princ Pract. 2006;15(2):102-5. doi: 10.1159/000090912.
4
HR2 haplotype in Arab population and patients with venous thrombosis in Kuwait.阿拉伯人群中的HR2单倍型与科威特静脉血栓形成患者
J Thromb Haemost. 2005 Jul;3(7):1467-71. doi: 10.1111/j.1538-7836.2005.01326.x.
5
[Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].[深静脉血栓形成患者的活化蛋白C抵抗、莱顿突变、抗凝蛋白及纤维蛋白原水平]
Pol Arch Med Wewn. 2003 Jun;109(6):579-88.
6
Thrombosis risk in carriers of the factor V Leiden mutation: is it associated with a defined skin color?携带因子 V 莱顿突变的个体的血栓形成风险:是否与特定肤色相关?
Pathol Res Pract. 2011 Nov 15;207(11):671-3. doi: 10.1016/j.prp.2011.07.013. Epub 2011 Oct 13.
7
[Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].[活化蛋白C抵抗与静脉血栓形成倾向:德国人群的分子遗传学患病率研究]
Dtsch Med Wochenschr. 1999 Jun 25;124(25-26):783-7. doi: 10.1055/s-2007-1024412.
8
Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.一项基于功能性凝血酶原时间检测法对一组意大利静脉血栓形成患者中因子V莱顿突变携带者进行鉴定的临床评估。
Blood Coagul Fibrinolysis. 2007 Oct;18(7):603-10. doi: 10.1097/MBC.0b013e3282891e2f.
9
Prevalence of factor V G1691A (Leiden) and prothrombin G20210A polymorphisms among apparently healthy Jordanians.表面健康的约旦人中因子V G1691A(莱顿)和凝血酶原G20210A基因多态性的患病率。
Neuro Endocrinol Lett. 2007 Oct;28(5):699-703.
10
The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.凝血因子V的HR2单倍型:对凝血因子V水平、标准化活化蛋白C敏感率及静脉血栓形成风险的影响
Thromb Haemost. 2000 Apr;83(4):577-82.

引用本文的文献

1
Determination of vWF, ADAMTS-13 and Thrombospondin-1 in Venous Thromboembolism and Relating Them to the Presence of Factor V Leiden Mutation.测定静脉血栓栓塞症中 vWF、ADAMTS-13 和血栓调节蛋白-1,并将其与因子 V Leiden 突变的存在相关联。
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296231223195. doi: 10.1177/10760296231223195.
2
Epidemiology of activated protein C resistance and factor v leiden mutation in the mediterranean region.地中海地区活化蛋白 C 抵抗和因子 V 莱顿突变的流行病学。
Mediterr J Hematol Infect Dis. 2011;3(1):e2011037. doi: 10.4084/MJHID.2011.037. Epub 2011 Sep 8.
3
Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals.
科威特国民中因子 V 莱顿突变的患病率存在种族差异。
Mol Biol Rep. 2011 Aug;38(6):3623-8. doi: 10.1007/s11033-010-0474-7. Epub 2010 Nov 21.